KURA

Tipifarnib

Chronic Myelomonocytic Leukemia

Phase 2

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Tipifarnib for Chronic Myelomonocytic Leukemia 


WHAT IS THE NEXT CATALYST EVENT?

  • WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Tipifarnib is a potent, selective and orally bioavailable inhibitor of the enzyme farnesyl transferase. Tipifarnib was previously studied in more than 5,000 cancer patients and demonstrated compelling and durable anti-cancer activity in certain patients with a manageable side effect profile.

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon